{name}
{subtitle}
Evaluation of Pembrolizumab (MK-3475) or Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008)
city
~32 mi. (Rostov-na-Donu, Russia, +30 more cities)
facility
Rostov Cancer Research Institute ( Site 1014)
drug
MK-1308A, +4 more drugs
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
city
~63 mi. (Khmelnytskyi, Ukraine, +176 more cities)
facility
MNE "Khmelnytskyi regional antitumor center" ( Site 2365)
condition
Endometrial Carcinoma, +1 more condition
drug
chemotherapy, +2 more drugs
drug type
chemotherapy, +2 more types
A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
city
~63 mi. (Khmelnytskyi, Ukraine, +160 more cities)
facility
Communal non-profit enterprise "Khmelnytskyi Regional Antitumor Center" of Khmelnytskoyi Regional Council
condition
Fallopian Tube Carcinoma, +2 more conditions
drug type
chemotherapy, +1 more type